Boiron SA (BON) Stock Price & Analysis
BON Stock Chart & Stats
- Day’s Range
- EUR 18.30 - EUR 18.30
- 52-Week Range
- EUR 16.50 - EUR 31.35
- Previous Close
- EUR 18.10
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 327.60M
- Enterprise Value
- EUR 454.08M
- Total Cash (Recent Filing)
- EUR 50.67M
- Total Debt (Recent Filing)
- EUR 23.80M
- Price to Earnings (P/E)
- 12.6
- Beta
- -0.07
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 7.32%
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage gives Boiron substantial financial flexibility and reduces the burden of interest and refinancing costs. This conservative capital structure can help the company withstand operating volatility while preserving capacity to invest, maintain products, or return cash to shareholders.
Positive Cash Generation
Positive operating and free cash flow across the reported periods indicates that Boiron’s operations have generally converted activity into internally generated funds. That supports ongoing business needs and provides a durable funding source, even though the pace of cash generation varies.
Established Pharmacy Distribution
A branded consumer-health portfolio supported by pharmacy distribution gives Boiron an established route to customers and recurring access to self-managed healthcare demand. Its domestic and international footprint can support resilience by spreading sales across channels and geographies.
Bears Say
Severe Revenue Contraction
The severe reported 2025 revenue contraction and broader history of uneven declines weaken visibility into Boiron’s underlying demand. Persistent top-line instability can limit operating leverage, complicate planning, and make future earnings less dependable even when profitability improves.
Volatile Free Cash Flow
Sharp year-to-year swings and the 2025 free-cash-flow decline make internally generated funding less predictable. Lower cash conversion consistency can constrain reinvestment and shareholder distributions, while increasing reliance on the company’s balance-sheet flexibility during weaker operating periods.
Shrinking Asset Base
Declining assets and equity, combined with an uneven profit trajectory, suggest that the company’s financial base has not expanded consistently. If this pattern persists, it could reduce capacity to support growth and leave future returns more dependent on stabilizing operations.
BON FAQ
What was Boiron SA’s price range in the past 12 months?
What is Boiron SA’s market cap?
When is Boiron SA’s upcoming earnings report date?
How were Boiron SA’s earnings last quarter?
Is Boiron SA overvalued?
Does Boiron SA pay dividends?
What is Boiron SA’s EPS estimate?
How many shares outstanding does Boiron SA have?
What happened to Boiron SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Boiron SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Boiron SA
Boiron S.A. is a global pharmaceutical company specializing in the production and distribution of homeopathic remedies across France, Europe, North America, and other international markets. Its extensive product portfolio encompasses a range of non-prescription, proprietary, and well-known branded homeopathic treatments. Noteworthy branded offerings include Oscillococcinum, designed to alleviate flu-like symptoms such as fever, chills, headaches, and body aches; Stodal and Stodaline, formulated for cough relief; Arnigel, providing topical support for minor, closed-wound traumas; Camilia, a solution for infant teething discomfort; and Sédatif PC, aimed at managing anxiety, emotional distress, and mild sleep disturbances. Furthermore, its homeopathic range features Coryzalia for addressing cold symptoms and rhinitis; Homéoptic, which targets eye discomfort and irritation in both adults and children; and Homéovox, developed for vocal issues. Beyond its core homeopathic line, Boiron also supplies dietary supplements; Dermoplasmine products (stick, balm, and mousse) for dry skin and lips; Mag' Nuit, an aid for promoting sleep; Arnitrosium for joint pain management; Castor Equi Boiron ointment for cracked skin; and Storinyl syrup for cold symptoms. The company's diverse inventory extends to herbal remedies, exemplified by Canephron, which supports increased urine production and improved urinary tract function; moisturizing lotions for babies; and medical devices, such as COVID-19 self-testing kits and rapid antigen tests. Boiron distributes its extensive product catalog through a comprehensive network encompassing distribution centers, independent pharmacies, pharmacy chains, wholesale partners, grocery and drugstores, specialized health food outlets, and various online retail platforms. Established in 1932, Boiron S.A. maintains its corporate headquarters in Messimy, France.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Pascal Houdayer
- Employees
- 2,623
- Website
- www.boiron.com
- Address
- 2, avenue de l’Ouest Lyonnais, Messimy, AR, 69510, FR
Boiron SA (BON) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 4 | 11 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 5 | 0 | 7 |
